Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/telomeres-and-telomerase.md — the filesystem corpus, unchanged. Not an edit.
12.1 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["longevity"]categories: ["longevity"]tags: ["aging", "telomeres", "cancer", "cell biology", "biomarkers", "mechanisms"]tags: ["aging", "telomeres", "cancer", "cell biology", "biomarkers", "mechanisms"]summary: "Repetitive DNA caps that shorten with each cell division, and the enzyme that rebuilds them, linking division limits, cancer risk, and a contested marker of aging."summary: "Repetitive DNA caps that shorten with each cell division, and the enzyme that rebuilds them, linking division limits, cancer risk, and a contested marker of aging."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "Human genetics ties telomerase mutations to the short telomere syndromes, and Mendelian randomization ties inherited longer telomeres to higher cancer risk; no trial has tested telomerase therapy for aging in people."humanEvidence: "Human genetics ties telomerase mutations to the short telomere syndromes, and Mendelian randomization ties inherited longer telomeres to higher cancer risk; no trial has tested telomerase therapy for aging in people."issues: ["The self-experimental telomerase gene therapy episode is described without a source."]issues: ["The self-experimental telomerase gene therapy episode is described without a source."]------lines 27–33 → 27–3813 unchanged lines not shown
}}`````` **Telomeres and telomerase** are, respectively, the repetitive nucleotide sequences and associated proteins that cap the ends of linear chromosomes, and the reverse transcriptase that extends them. Telomeres shorten each time a somatic cell divides; when they become critically short the cell triggers a DNA damage response and enters [[cellular-senescence|senescence]] or apoptosis. Telomere attrition is one of the [[hallmarks-of-aging]], but its causal weight in normal human aging is smaller and more disputed than popular accounts suggest.**Telomeres and telomerase** are, respectively, the repetitive nucleotide sequences and associatedproteins that cap the ends of linear chromosomes, and the reverse transcriptase that extends them.Telomeres shorten each time a somatic cell divides. When they become critically short, the celltriggers a DNA damage response and enters [[cellular-senescence|senescence]] or apoptosis. Telomereattrition is one of the [[hallmarks-of-aging]], but its causal weight in normal human aging issmaller and more disputed than popular accounts suggest. ```figure```figure{"key": "telomeres-chromosome", "caption": "Telomeres cap each chromosome end. They shorten with division in most human somatic cells, which makes them a correlate of ageing and not obviously a cause."}{"key": "telomeres-chromosome", "caption": "Telomeres cap each chromosome end. They shorten with division in most human somatic cells, which makes them a correlate of ageing and not obviously a cause."}lines 35–49 → 40–721 unchanged line not shown
## Structure and function## Structure and function Human telomeres consist of thousands of tandem TTAGGG repeats ending in a single-stranded 3′ overhang that folds back to form a lasso-like t-loop. Six proteins — TRF1, TRF2, POT1, TIN2, TPP1 and RAP1, collectively the shelterin complex — bind the repeats and hide the chromosome end from the repair machinery. Without shelterin, the cell reads a natural chromosome terminus as a double-strand break and attempts to fuse it to another chromosome, producing the end-to-end fusions and breakage cycles that characterize genomic crisis.Human telomeres consist of thousands of tandem TTAGGG repeats ending in a single-stranded 3′overhang, which folds back to form a lasso-like t-loop. Six proteins, TRF1, TRF2, POT1, TIN2, TPP1and RAP1, together called the shelterin complex, bind the repeats and hide the chromosome end fromthe repair machinery. Without shelterin, the cell reads a natural chromosome terminus as adouble-strand break and tries to fuse it to another chromosome, producing the end-to-end fusions andbreakage cycles that characterize genomic crisis. The capping function, not the length as such, is what matters. A telomere can be long and dysfunctional if shelterin is disrupted, and short telomeres in a cell with intact capping may not signal damage until a threshold is crossed. The relationship between average telomere length and cellular behaviour is therefore indirect: it is the shortest telomere in a cell, not the mean, that determines when arrest occurs.What matters is the capping function, not the length as such. A telomere can be long anddysfunctional if shelterin is disrupted, and short telomeres in a cell with intact capping may notsignal damage until a threshold is crossed. Average telomere length is therefore only indirectlyrelated to cellular behaviour: the shortest telomere in a cell, not the mean, determines when arrestoccurs. ## The end-replication problem and the Hayflick limit## The end-replication problem and the Hayflick limit DNA polymerase cannot replicate the extreme 5′ end of a lagging strand, so each round of replication removes a small stretch of terminal sequence. James Watson described the geometry of this in 1972, and Alexey Olovnikov independently proposed that it would impose a division counter on somatic cells and explain the replicative limit Leonard Hayflick had observed in cultured human fibroblasts.[^olovnikov1973] Human somatic cells in culture typically manage a few dozen population doublings before arresting.DNA polymerase cannot replicate the extreme 5′ end of a lagging strand, so each round of replicationremoves a small stretch of terminal sequence. James Watson described the geometry of this in 1972.Alexey Olovnikov independently proposed that it would impose a division counter on somatic cells andwould explain the replicative limit Leonard Hayflick had observed in cultured humanfibroblasts.[^olovnikov1973] Human somatic cells in culture typically manage a few dozen populationdoublings before arresting. Introducing the catalytic subunit of telomerase into normal human cells prevents that arrest and allows indefinite proliferation, which confirmed the causal link between telomere maintenance and the replicative limit.[^bodnar1998] This is the basis of most immortalized cell lines used in research, and telomerase reactivation is part of what makes [[induced-pluripotent-stem-cells|induced pluripotent stem cells]] proliferate without limit.Introducing the catalytic subunit of telomerase into normal human cells prevents that arrest andallows indefinite proliferation, which confirmed the causal link between telomere maintenance andthe replicative limit.[^bodnar1998] Most immortalized cell lines used in research rest on this, andtelomerase reactivation is part of what lets[[induced-pluripotent-stem-cells|induced pluripotent stem cells]] proliferate without limit. ## Telomerase## Telomerase lines 57–91 → 80–1667 unchanged lines not shown
]]`````` Telomerase is a ribonucleoprotein: the protein subunit TERT copies a template carried within the RNA subunit TERC. It is active in germ cells, embryonic stem cells, and — at lower levels — in adult stem and progenitor compartments and activated lymphocytes. Most differentiated human somatic cells express little or none, which is why they age replicatively.Telomerase is a ribonucleoprotein in which the protein subunit TERT copies a template carried withinthe RNA subunit TERC. It is active in germ cells and embryonic stem cells, and at lower levels inadult stem and progenitor compartments and in activated lymphocytes. Most differentiated humansomatic cells express little or none, which is why they age replicatively. Loss-of-function mutations in telomerase components and in shelterin cause the short telomere syndromes, a spectrum that includes dyskeratosis congenita, aplastic anaemia, and a substantial fraction of familial idiopathic pulmonary fibrosis.[^armanios2012] These disorders provide the cleanest human evidence that telomere maintenance matters: patients show premature failure of exactly the high-turnover tissues that depend on it, connecting the mechanism directly to [[stem-cell-exhaustion|stem cell exhaustion]]. They do not show that ordinary aging is telomere-driven, since the affected tissues are a subset and the phenotype is not general.Loss-of-function mutations in telomerase components and in shelterin cause the short telomeresyndromes, a spectrum that includes dyskeratosis congenita, aplastic anaemia and a substantialfraction of familial idiopathic pulmonary fibrosis.[^armanios2012] These disorders are the cleanesthuman evidence that telomere maintenance matters. Patients show premature failure of exactly thehigh-turnover tissues that depend on it, which ties the mechanism directly to[[stem-cell-exhaustion|stem cell exhaustion]]. They do not show that ordinary aging is driven bytelomeres, since only a subset of tissues is affected and the phenotype is not general. ## A weak biomarker## A weak biomarker Average leukocyte telomere length is easy to sell as a measure of [[biological-age]] and difficult to defend as one. Inter-individual variation at any given chronological age is large relative to the average annual rate of loss, so a single measurement carries little information about an individual. Measurement methods disagree: quantitative PCR, the cheapest approach and the one behind most consumer tests, has poor within-sample reproducibility compared with terminal restriction fragment analysis or flow-FISH, and results are not comparable across laboratories. Longitudinal studies sometimes report telomere lengthening in individuals over follow-up intervals, which is a strong sign of measurement noise.Average leukocyte telomere length is easy to sell as a measure of [[biological-age]] and difficultto defend as one. At any given chronological age, variation between individuals is large relative tothe average annual rate of loss, so a single measurement says little about an individual.Measurement methods disagree. Quantitative PCR, the cheapest approach and the one behind mostconsumer tests, has poor within-sample reproducibility compared with terminal restriction fragmentanalysis or flow-FISH, and results are not comparable across laboratories. Longitudinal studiessometimes report telomeres lengthening in individuals over the follow-up interval, a strong sign ofmeasurement noise. > [!caution] Contested> [!caution] Contested> Consumer telomere tests, sold through the same [[consumer-blood-testing|direct-to-consumer testing]]> Consumer telomere tests, sold through the same> channels as broad blood panels, report a length and an implied "cellular age". No professional body endorses telomere length as a clinical measure of aging outside the diagnosis of telomere biology disorders, and [[epigenetic-clock|methylation-based clocks]] outperform it as mortality predictors in most head-to-head comparisons.> [[consumer-blood-testing|direct-to-consumer testing]] channels as broad blood panels, report a> length and an implied "cellular age". No professional body endorses telomere length as a clinical> measure of aging outside the diagnosis of telomere biology disorders, and in most head-to-head> comparisons [[epigenetic-clock|methylation-based clocks]] outperform it as mortality predictors. Associations between telomere length and lifestyle factors such as [[exercise-and-aging|physical activity]] or stress have been widely reported and are generally small, inconsistently replicated, and vulnerable to confounding. The field's own retrospective assessment is that early effect sizes were inflated by small samples and selective reporting, a pattern common across candidate [[aging-biomarkers|aging biomarkers]].Associations between telomere length and lifestyle factors such as[[exercise-and-aging|physical activity]] or stress have been widely reported. They are generallysmall, inconsistently replicated and vulnerable to confounding. The field's own retrospectiveassessment is that small samples and selective reporting inflated the early effect sizes, a patterncommon across candidate [[aging-biomarkers|aging biomarkers]]. ## The cancer tradeoff## The cancer tradeoff The large majority of human cancers reactivate telomerase, most often through mutations in the *TERT* promoter that create new transcription factor binding sites; the remainder maintain telomeres through a recombination-based mechanism called alternative lengthening of telomeres. Unlimited division requires solving the end-replication problem, and telomere attrition is therefore a genuine tumour-suppressive barrier in long-lived, large-bodied species.The large majority of human cancers reactivate telomerase, most often through mutations in the *TERT*promoter that create new transcription factor binding sites. The rest maintain telomeres through arecombination-based mechanism called alternative lengthening of telomeres. Unlimited divisionrequires a solution to the end-replication problem, so in long-lived, large-bodied species telomereattrition is a genuine barrier against tumours. This makes telomerase therapy for aging structurally awkward. Mendelian randomization studies using genetic variants that raise telomere length find increased risk of several cancers, notably glioma and melanoma, alongside modestly reduced risk of some non-neoplastic conditions.[^tmrc2017] Germline *POT1* mutations that lengthen telomeres cause familial cancer predisposition syndromes. Any intervention that adds telomere reserve across the body would be pushing on a trait for which natural selection appears to have found a compromise.That makes telomerase therapy for aging structurally awkward. Mendelian randomization studies usinggenetic variants that raise telomere length find increased risk of several cancers, glioma andmelanoma among them, alongside modestly reduced risk of some non-neoplastic conditions.[^tmrc2017]Germline *POT1* mutations that lengthen telomeres cause familial cancer predisposition syndromes.Any intervention that added telomere reserve across the body would be pushing on a trait for whichnatural selection appears to have settled on a compromise. ## Therapeutic attempts## Therapeutic attempts Work in mice has been more encouraging than the cancer argument would suggest, with the caveat that laboratory mice have very long telomeres and constitutive telomerase in many tissues, making them a poor model for the human situation. Systemic delivery of a *Tert* transgene using an [[aav-vectors|adeno-associated viral vector]] to adult mice extended median lifespan and improved several health measures without an observed increase in cancer incidence.[^bdj2012] Similar work in cancer-resistant mouse backgrounds also extended lifespan.Work in mice has been more encouraging than the cancer argument would suggest, with a caveat:laboratory mice have very long telomeres and constitutive telomerase in many tissues, which makesthem a poor model for the human situation. Systemic delivery of a *Tert* transgene to adult miceusing an [[aav-vectors|adeno-associated viral vector]] extended median lifespan and improved severalhealth measures without an observed increase in cancer incidence.[^bdj2012] Similar work incancer-resistant mouse backgrounds also extended lifespan. In humans the record is thinner and less reputable. Supplements marketed as telomerase activators, principally cycloastragenol derivatives, rest on small studies with weak endpoints and are sold under the [[dietary-supplements|rules that govern supplements]] rather than as drugs. Self-experimental telomerase [[gene-therapy-for-aging|gene therapy]] outside clinical trials has been publicized by at least one biotechnology executive, with self-reported telomere measurements as the only outcome and no independent verification. Meanwhile the pharmaceutical use of telomere biology has gone the opposite direction: the first approved drug in the area inhibits telomerase to treat a haematological malignancy.The human record is thinner and less reputable. Supplements marketed as telomerase activators,mainly cycloastragenol derivatives, rest on small studies with weak endpoints and are sold under the[[dietary-supplements|rules that govern supplements]] rather than as drugs. At least onebiotechnology executive has publicized self-experimental telomerase[[gene-therapy-for-aging|gene therapy]] outside clinical trials, with self-reported telomeremeasurements as the only outcome and no independent verification. Meanwhile, pharmaceutical use oftelomere biology has gone the other way: the first approved drug in the area inhibits telomerase totreat a haematological malignancy. ## Open problems## Open problems The comparative biology does not fit a simple story. Mice have far longer telomeres than humans and live roughly two years. Some [[negligible-senescence|negligibly senescent]] species maintain telomerase in somatic tissue and control cancer by other means. Whether telomere attrition contributes materially to the trajectory of a normally aging human, as opposed to setting a limit in specific high-turnover compartments, is not resolved, and the question bears directly on how much of the [[sens-research-foundation|damage-repair]] agenda and the [[geroscience-hypothesis|geroscience]] programme should be allocated to it. The one point of agreement is that raising telomerase everywhere is not a plausible route to [[maximum-human-lifespan|extended maximum lifespan]] without a solution to the cancer problem, and no such solution exists.The comparative biology does not fit a simple story. Mice have far longer telomeres than humans andlive roughly two years. Some [[negligible-senescence|negligibly senescent]] species maintaintelomerase in somatic tissue and control cancer by other means. It is not resolved whether telomereattrition contributes materially to the course of normal human aging or only sets a limit inspecific high-turnover compartments. The answer bears directly on how much of the[[sens-research-foundation|damage-repair]] agenda and the [[geroscience-hypothesis|geroscience]]programme should go to telomeres. The one point of agreement is that raising telomerase everywhereis not a plausible route to [[maximum-human-lifespan|extended maximum lifespan]] without a solutionto the cancer problem, and no such solution exists. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
89 lines are the same in both revisions, and 42 of them are not shown. Neither revision here is necessarily the current article — read Telomeres and telomerase for the text this wiki stands behind today.